USPTO serial 88768088
NOURIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 16, 2021
- Examiner
- MAYES, LAURIE ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NOURIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shuo Che Chou
Shuo Che Chou SINORICA LLC DBA THOUGHTS TO PAPER20251 CENTURY BLVD STE 140GERMANTOWN, MD 20874UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes | ACTIVE | Oct 19, 2020 |
| 005 | protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes | ACTIVE | Oct 19, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 16, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 16, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 15, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 14, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 14, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 13, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 22, 2020 | IUAF | USE AMENDMENT FILED | — |
| Dec 22, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 4, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 9, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 9, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 20, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 5, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 25, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 24, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 24, 2020 | NWAP | NEW APPLICATION ENTERED | — |